Comparative Pharmacology
Head-to-head clinical analysis: MICRODERM versus RETIN A MICRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRODERM versus RETIN A MICRO.
MICRODERM vs RETIN-A-MICRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICRODERM is a brand name for tretinoin, a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene transcription to promote keratinocyte differentiation, reduce proliferation, and normalize desquamation, thereby decreasing comedone formation and inflammation.
Retinoid agonist that binds to and activates retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and keratinization, leading to normalization of follicular keratinization and reduced comedone formation.
MICRODERM is not a recognized pharmaceutical agent; no standard dosing information available.
Topical, apply a pea-sized amount to the entire face once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-15 h); requires dose adjustment in renal impairment when CrCl <30 mL/min.
Terminal elimination half-life is approximately 0.5-2 hours after topical application, though prolonged due to slow release from microsphere formulation. Clinical context: rapid clearance limits systemic accumulation.
Renal excretion accounts for 70% as unchanged drug, biliary/fecal elimination 20%, hepatic metabolism 10%.
Tretinoin is metabolized in the liver via CYP450 enzymes, primarily CYP2A6 and CYP3A4. Metabolites are eliminated via bile and feces (approximately 60%) and urine (approximately 30%), with less than 1% of unchanged drug excreted renally.
Category C
Category C
Topical Retinoid
Topical Retinoid